These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25505208)

  • 41. Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
    Maciel LMZ; Magalhães PKR
    Arch Endocrinol Metab; 2017; 61(4):398-402. PubMed ID: 28658345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sorafenib for the treatment of thyroid cancer: an updated review.
    Krajewska J; Handkiewicz-Junak D; Jarzab B
    Expert Opin Pharmacother; 2015 Mar; 16(4):573-83. PubMed ID: 25605317
    [TBL] [Abstract][Full Text] [Related]  

  • 43. More effective agents still needed for progressive radioiodine-refractory differentiated thyroid cancer.
    Shen CT; Qiu ZL; Luo QY
    Endocr Relat Cancer; 2014 Apr; 21(2):L3-4. PubMed ID: 24639563
    [No Abstract]   [Full Text] [Related]  

  • 44. Targeted treatments of radio-iodine refractory differentiated thyroid cancer.
    de la Fouchardière C
    Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S34-9. PubMed ID: 26826481
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib.
    Shen Y; Ruan M; Luo Q; Yu Y; Lu H; Zhu R; Chen L
    Thyroid; 2012 Aug; 22(8):856-60. PubMed ID: 22793259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer.
    Machens A; Dralle H
    J Clin Oncol; 2010 Oct; 28(28):e534: author reply e535-6. PubMed ID: 20713862
    [No Abstract]   [Full Text] [Related]  

  • 47. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Wilson L; Huang W; Chen L; Ting J; Cao V
    Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of lenvatinib in treating thyroid cancer.
    Krajewska J; Kukulska A; Jarzab B
    Expert Opin Pharmacother; 2016 Aug; 17(12):1683-91. PubMed ID: 27398740
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cabozantinib approved for advanced medullary thyroid cancer.
    Traynor K
    Am J Health Syst Pharm; 2013 Jan; 70(2):88. PubMed ID: 23292257
    [No Abstract]   [Full Text] [Related]  

  • 50. Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome.
    Barroso-Sousa R; Lerario AM; Evangelista J; Papadia C; Lourenço DM; Lin CS; Kulcsar MA; Fragoso MC; Hoff AO
    Thyroid; 2014 Jun; 24(6):1062-6. PubMed ID: 24499195
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.
    Matrone A; Valerio L; Pieruzzi L; Giani C; Cappagli V; Lorusso L; Agate L; Puleo L; Viola D; Bottici V; Del Re M; Molinaro E; Danesi R; Elisei R
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):319-334. PubMed ID: 28911728
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selective use of sorafenib in the treatment of thyroid cancer.
    Pitoia F; Jerkovich F
    Drug Des Devel Ther; 2016; 10():1119-31. PubMed ID: 27042004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
    Haddad RI; Bischoff L; Ball D; Bernet V; Blomain E; Busaidy NL; Campbell M; Dickson P; Duh QY; Ehya H; Goldner WS; Guo T; Haymart M; Holt S; Hunt JP; Iagaru A; Kandeel F; Lamonica DM; Mandel S; Markovina S; McIver B; Raeburn CD; Rezaee R; Ridge JA; Roth MY; Scheri RP; Shah JP; Sipos JA; Sippel R; Sturgeon C; Wang TN; Wirth LJ; Wong RJ; Yeh M; Cassara CJ; Darlow S
    J Natl Compr Canc Netw; 2022 Aug; 20(8):925-951. PubMed ID: 35948029
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma.
    Blair HA; Plosker GL
    Target Oncol; 2015 Mar; 10(1):171-8. PubMed ID: 25742918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.
    Rajabi S; Hedayati M
    Mol Diagn Ther; 2017 Dec; 21(6):607-620. PubMed ID: 28698976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeted therapy for advanced or metastatic differentiated thyroid carcinoma.
    Wirth LJ
    Clin Adv Hematol Oncol; 2015 Apr; 13(4 Suppl 4):9-16. PubMed ID: 26430870
    [No Abstract]   [Full Text] [Related]  

  • 57. 68Ga DOTATATE PET/CT in Differentiated Thyroid Carcinoma With Fibular Metastasis and Mixed Response to Sorafenib.
    Basu S; Joshi A
    Clin Nucl Med; 2016 Oct; 41(10):772-3. PubMed ID: 27500511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.
    Felicetti F; Nervo A; Piovesan A; Berardelli R; Marchisio F; Gallo M; Arvat E
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1093-1098. PubMed ID: 28988510
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
    Starenki D; Hong SK; Wu PK; Park JI
    Cancer Biol Ther; 2017 Jul; 18(7):473-483. PubMed ID: 28475408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
    Schneider TC; Kapiteijn E; van Wezel T; Smit JWA; van der Hoeven JJM; Morreau H
    BMC Cancer; 2016 Jan; 16():31. PubMed ID: 26786320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.